Genitourinary cancers updates: highlights from ASCO 2023

Significant scientific advances in immunotherapy and targeted therapy approaches have improved clinical outcomes and increased treatment options for patients with genitourinary (GU) malignancies. We highlight the clinical trial developments released at the ASCO 2023 annual meeting, including PARP in...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Qian, Sheffield, Hollie, Taasan, Sean M., Wang, Andrew Z., Zhang, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662513/
https://www.ncbi.nlm.nih.gov/pubmed/37990343
http://dx.doi.org/10.1186/s13045-023-01511-8
_version_ 1785148555243028480
author Qin, Qian
Sheffield, Hollie
Taasan, Sean M.
Wang, Andrew Z.
Zhang, Tian
author_facet Qin, Qian
Sheffield, Hollie
Taasan, Sean M.
Wang, Andrew Z.
Zhang, Tian
author_sort Qin, Qian
collection PubMed
description Significant scientific advances in immunotherapy and targeted therapy approaches have improved clinical outcomes and increased treatment options for patients with genitourinary (GU) malignancies. We highlight the clinical trial developments released at the ASCO 2023 annual meeting, including PARP inhibitors for prostate cancer, antibody drug conjugates and fibroblast growth factor receptor inhibitors for urothelial cancer, and HIF2a inhibitors for renal cell carcinoma. Novel agents such as bispecific antibodies, chimeric antigen receptor T-cells, and radiopharmaceuticals are currently in early phase development and also have high potential impact for the GU cancer landscape. With more treatment options, the field will need to define best treatment sequencing to optimize outcomes for each patient.
format Online
Article
Text
id pubmed-10662513
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106625132023-11-21 Genitourinary cancers updates: highlights from ASCO 2023 Qin, Qian Sheffield, Hollie Taasan, Sean M. Wang, Andrew Z. Zhang, Tian J Hematol Oncol Editorial Significant scientific advances in immunotherapy and targeted therapy approaches have improved clinical outcomes and increased treatment options for patients with genitourinary (GU) malignancies. We highlight the clinical trial developments released at the ASCO 2023 annual meeting, including PARP inhibitors for prostate cancer, antibody drug conjugates and fibroblast growth factor receptor inhibitors for urothelial cancer, and HIF2a inhibitors for renal cell carcinoma. Novel agents such as bispecific antibodies, chimeric antigen receptor T-cells, and radiopharmaceuticals are currently in early phase development and also have high potential impact for the GU cancer landscape. With more treatment options, the field will need to define best treatment sequencing to optimize outcomes for each patient. BioMed Central 2023-11-21 /pmc/articles/PMC10662513/ /pubmed/37990343 http://dx.doi.org/10.1186/s13045-023-01511-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Editorial
Qin, Qian
Sheffield, Hollie
Taasan, Sean M.
Wang, Andrew Z.
Zhang, Tian
Genitourinary cancers updates: highlights from ASCO 2023
title Genitourinary cancers updates: highlights from ASCO 2023
title_full Genitourinary cancers updates: highlights from ASCO 2023
title_fullStr Genitourinary cancers updates: highlights from ASCO 2023
title_full_unstemmed Genitourinary cancers updates: highlights from ASCO 2023
title_short Genitourinary cancers updates: highlights from ASCO 2023
title_sort genitourinary cancers updates: highlights from asco 2023
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662513/
https://www.ncbi.nlm.nih.gov/pubmed/37990343
http://dx.doi.org/10.1186/s13045-023-01511-8
work_keys_str_mv AT qinqian genitourinarycancersupdateshighlightsfromasco2023
AT sheffieldhollie genitourinarycancersupdateshighlightsfromasco2023
AT taasanseanm genitourinarycancersupdateshighlightsfromasco2023
AT wangandrewz genitourinarycancersupdateshighlightsfromasco2023
AT zhangtian genitourinarycancersupdateshighlightsfromasco2023

Ejemplares similares